CTLA4-Ig promising in rheumatoid arthritis

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1414, 2003-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis

By Emery Paul  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 4, 2003-04 ,pp. : 673-681

Informa Healthcare

Access to resources Recommend Favorite

Mechanisms of CTLA-4-Ig in Tolerance Induction

By  

Current Pharmaceutical Design, Vol. 12, Iss. 2, 2006-01 ,pp. : 149-160

Bentham Science Publishers

Access to resources Recommend Favorite

CTLA4-Ig: a novel immunosuppressive agent

By Najafian N.   Sayegh M.H.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 9, 2000-09 ,pp. : 2147-2157

Informa Healthcare

Access to resources Recommend Favorite

IL-33: a promising therapeutic target for rheumatoid arthritis?

By Yuan Feng-Lai   Li Xia   Lu Wei-Guo   Li Cheng-Wan   Xu Rui-Sheng   Dong Jian  

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 5, 2011-05 ,pp. : 529-534

Informa Healthcare

Access to resources Recommend Favorite

Biological therapies promising in juvenile rheumatoid arthritis

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 21, Iss. 2, 2005-02 ,pp. : 8-11

Adis International

Access to resources Recommend Favorite